Use of silkworms for identification of drug candidates having appropriate pharmacokinetics from plant sources by Asami, Yukihiro et al.
Asami et al. BMC Pharmacology 2010, 10:7
http://www.biomedcentral.com/1471-2210/10/7
Open Access METHODOLOGY ARTICLE
© 2010 Asami et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Methodology article Use of silkworms for identification of drug 
candidates having appropriate pharmacokinetics 
from plant sources
Yukihiro Asami, Ryo Horie, Hiroshi Hamamoto and Kazuhisa Sekimizu*
Abstract
Background: We use silkworms to evaluate therapeutic effects of drug candidates. Our previous reports have revealed 
that there are common mechanisms of pharmacokinetics of chemicals in silkworms and mammals. In this report, we 
attempt to establish a method by using silkworms to identify chemicals from plant extracts which are absorbed from 
intestine and also stably exist in body fluids.
Results: Three compounds were detected in the silkworm hemolymph by HPLC analysis after midgut injection of 
acetone extracts of seihi, an herbal medicine obtained from orange peel. Analyses with MS and NMR revealed that the 
compounds were nobiletin, heptamethoxyflavone, and tangeretin. These compounds are reported to be stable in 
mammalian blood. The half-life of each of these compounds in the silkworm hemolymph was 18, 26 and 34 h, 
respectively.
Conclusions: These findings suggest that silkworms can be used as a model animal to easily identify compounds with 
appropriate pharmacokinetic behavior.
Background
Appropriate behavior in human bodies from the view of
pharmacokinetics is an essential feature for drug candi-
dates, since it is needed for therapeutic effects of the
compounds [1]. In fact, most drug candidates screened by
in vitro systems have problems in pharmacokinetics, and
therefore, they do not show therapeutic effects in disease
models with animals [2]. Mammals like mice and rats are
chosen as model animals. A problem is that it is not easy
to examine pharmacokinetics of a large number of drug
candidates at early stages of drug development, since a
huge amount of financial cost are needed to take care of
mammals in laboratory facilities. It is also pointed out
that sacrificing a large number of mammals causes ethical
problems from a view of animal protection. The latter
point is coming to be serious so that it is going to be a
major factor to slow down the speed of drug development
in industrialized countries. To solve these problems, use
of invertebrates, which can be used with a large numbers
with low costs, is desired [3].
We are currently proposing usefulness of silkworms to
evaluate therapeutic effects of drug candidates. The size
of silkworms is large enough to handle so that one can
easily inject fixed volume of sample solution with
syringes into hemolymph, a blood of silkworms. Two dis-
tinguishable protocols for injection of sample solution are
available for silkworms; i.h. (intra hemolymph) and i.m.
(intra midgut) injections. The former corresponds to
injection into vein (i.v.), the latter to oral administration
(p.o.) in humans. Pharmacologic experiments with iso-
lated organs like midgut and fat body, which correspond
to intestine and liver of mammals, are possible with silk-
worms. Those techniques are not easily applicable for
fruit fly and nematoda, which are recently used as model
animals for diseases, due to their small bodies. We previ-
ously reported establishment of infection models of silk-
worm with pathogenic bacteria and true fungi [4]. We
demonstrated that the values of ED50, amounts of antibi-
otics needed for therapeutic effects to 50% of animals,
and LD50, amounts of chemicals needed to kill 50% of ani-
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mals, by the fixed amount of body weight of animals are
similar between silkworms and mammals [5]. We also
showed that silkworms have metabolic pathways with
cytochrome P450s and conjugation enzymes [6]. It is also
shown that the results of whether antibiotics can be
absorbed from intestine or not are similar in silkworms
and mammals [7]. These results suggest that there are
common mechanisms of pharmacokinetics of chemicals
between silkworms and mammals.
In this report, we describe our attempts to establish a
method by using silkworms to identify chemicals from
plant extracts which are absorbed from intestine and also
stably exist in body fluids. We injected samples into
midgut of silkworms, which corresponds to intestine in
mammals, and examined substances that were stably
exist in hemolymph. We identified three substances and
determined their structures. We further confirmed that
those substances stably exist in hemolymph of silkworm.
T o  o u r  k n o w l e d g e ,  t h i s  i s  t h e  f i r s t  r e p o r t  p r o p o s i n g  a
method to identify chemicals possessing appropriate
futures in pharmacokinetics.
Results
Detection of the compound which are absorbed from 
intestine and also stably exist in body fluids
Firstly, we performed that acetone extract (500 μl) of
seihi, an herbal medicine of orange peel from Citrus retic-
ulata Blanco, was injected into intestine of silkworm (Fig-
ure 1A). After 6 hrs incubation, hemolymph was
harvested from legs of larvae (Figure 1B). An equal vol-
ume of acetone was added, mixed vigorously, centrifuged,
and the supernatant was analyzed by HPLC. By compari-
son of HPLC chromatogram obtained by hemolymph of
silkworm injected with the acetone extract of seihi and
that with saline (Figure 2A), 3 peaks with 34.36 min, 34.75
min, and 36.07 min were identified as a material from
seihi (Figure 2B). Whole profiles of chromatography for
each sample are shown in additional file 1A and 1B.
Those 3 compounds were found as peaks of HPLC chro-
matogram of acetone extract of seihi at 34-39 min (addi-
tional file 2A). They are also observed by HPLC
chromatogram of hexane extract of seihi (additional file
2B). Therefore, those chemicals were originally present in
the seihi extract, and stably exist in silkworm hemolymph
after absorbed from midgut.
Purification of the three compounds
We tried to purify the above three compounds in a large
scale for structural determination. Seihi (100 g) was
extracted with 50% acetone (2 L), and acetone was
removed by evaporation. The fraction (1 L) was extracted
with an equal volume of n-hexane, and further purified by
preparative HPLC. The yields of the fractions of com-
pound A, B, and C at this stage were 11.6 mg, 21.1 mg,
and 23.5 mg, respectively. Each sample was further puri-
fied by preparative thin layer chromatography. The yields
of the final fractions of compound A, B, and C were 8.5
mg, 16.3 mg, and 19.1 mg, respectively (additional file 3).
Each fraction showed a single peak on HPLC (additional
file 4).
Figure 1 Methods for injecting and harvesting hemolymph. A: Injection of samples into silkworm midgut; B: Harvesting hemolymph from legs of 
silkworm.
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Determination of structure of the three compounds
We next try to determine structures of compound A, B,
and C. Mass-spectrometry analysis revealed molecular
masses of compound A, B, and C were 402, 432, and 372,
respectively. The results of 1H-NMR spectrum measure-
ment revealed the presence of hydrogen, characteristic
methoxy, and aromatic ring protons. Based on compari-
son with previously published data for ingredients of seihi
and compound A, B, and C measured both FAB-MS and
1H-NMR spectrum data [8,9] [Compound A (Nobiletin):
FAB-MS m/z 403 (M+H)+; 1H NMR (500 MHz, CDCl3),
δH 7.58 (dd, J = 2.0, 8.6 Hz, 1H), 7.42 (d, J = 2.0 Hz, 1H),
7.00 (d, J = 8.6 Hz, 1H), 6.62 (s, 1H), 4.11 (s, 3H), 4.03 (s,
3H), 3.98 (s, 3H), 3.97 (s, 3H), 3.96 (s, 6H). Compound B
(Heptamethoxyflavone): FAB-MS m/z 433 (M+H)+;  1H
NMR (500 MHz, CDCl3), δH 7.85 (dd, J = 2.0, 8.7 Hz, 1H),
7.81 (d, J = 2.0, 8.7 Hz, 1H), 7.02 (d, J = 8.7 Hz, 1H), 4.10
(s, 3H), 4.01 (s, 3H), 3.98 (s, 6H), 3.95 (s, 3H), 3.89 (s, 3H).
Compound C (Tangeretin): FAB-MS m/z 373 (M+H)+; 1H
NMR (500 MHz, CDCl3), δH 7.88 (d, J = 8.6 Hz, 2H), 7.03
(d, J = 8.6 Hz, 2H), 6.61 (s, 1H), 4.11 (s, 3H), 4.03 (s, 3H),
3.95 (s, 6H), 3.89 (s, 3H).],we concluded that compound
A, B, and C were Nobiletin (C21H22O8, MW = 402), Hep-
tamethoxyflavone (C22H24O9, MW = 432), and Tangere-
tin (C20H20O7, MW = 372), respectively (Figure 3)
Pharmacokinetics of the three compounds in silkworm 
hemolymph
We assumed that their transport across midgut mem-
brane might not be blocked by molecular mass barriers
since the molecular masses of these compounds were
smaller than 450[6]. We also assumed that compound A,
B ,  a n d  C  w e r e  s t a b l e  i n  h e m o l y m p h ,  s i n c e  t h e y  w e r e
found in hemolymph of silkworm 6 hrs later after injec-
tion into midgut. To test the stability of the compounds in
hemolymph, we injected purified compound A, B, and C
into hemolymph of silkworm and examined their
amounts in hemolymph after appropriate period of injec-
tion. The concentration of compounds A, B, and C in
hemolymph was determined by HPLC. The results dem-
onstrated that concentrations of compound A, B, and C
in hemolymph decreased quickly soon after injection fol-
lowed by slow decrease at the second stage. The half-lives
of compound A, B, and C at the second stage were esti-
mated to be 18, 26, and 34 hrs, respectively (Figure 4).
Discussion
In this study, we demonstrated a method to identify
chemical compounds that show appropriate pharmacoki-
netics as drug candidates by using silkworm, an inverte-
brate animal. We injected an acetone extract of seihi into
midgut of silkworm, and identified three compounds that
appear and stably exist in hemolymph. The half-lives of
these compounds in hemolymph of silkworm were 18, 26,
and 34 hrs, indicating their stability in hemolymph.
Structural analysis demonstrated that they are
polymethoxyflavones with the flavonoid skeletons. Those
compounds were reported to have pharmacological
actions of anti-inflammation, anti-oxidation, and anti-
malignancy[9-12]. Since they show interesting physiolog-
ical activities, researches examined pharmacokinetics of
the compounds in mammals. For instance, good charac-
ters as drug candidates of pharmacokinetics of nobiletin
and tangeretin in rats has been reported[9,13-15]. Half-
life of nobiletin in mouse blood was suggested to be lon-
ger than 24 hrs[14]. This means that those three com-
pounds identified as chemicals that show appropriate
pharmacokinetics in silkworms are compounds whose
pharmacokinetics is appropriate in mammals. In addi-
tion, we used this method to identify some compounds in
soil bacteria culture supernatant that exhibit stable phar-
macokinetics in silkworm hemolymph and are therefore
appropriate for further screening (manuscript in prepara-
tion).
An evaluation method of pharmacokinetics for a large
number of chemicals can be applied not only to plant
extract, but also to other natural sources including micro-
organisms and animals. The method is also useful to
identify such chemicals from chemical libraries contain-
ing a large number of synthetic organic compounds. The
most characteristic advantage of the method by using
silkworm is that one can inject test samples into both
hemolymph, a blood of larvae, and midgut, that corre-
sponds to intestine of mammals. The former corresponds
to intra vein injection, and the latter corresponds to oral
administration in humans. We previously reported that
Figure 2 Detection method of compounds in silkworm hemo-
lymph by HPLC. A) Magnified chromatogram of hemolymph of silk-
worm injected with saline. B) Magnified chromatogram of hemolymph 
of silkworm injected with an acetone extract of seihi. Asterisks indicate 
peaks from silkworm hemolymph. Arrows indicate peaks of specifically 
identified substances.
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there are common features in barriers by molecular mass
of midgut of silkworm and intestine of mammals[6].
Taken together with our present findings, a method by
using silkworms seems to be useful to screen drug candi-
dates that are effective by oral administration.
Conclusions
Appropriate features in pharmacokinetics are essential
for medicine to show therapeutic effects in disease mod-
els with animals. Importance of availability by oral
administration should be emphasized since it decreases
the burden of human patients. A problem is that the most
of compounds that adsorbed from intestine are unstable
in blood, so that unable to show therapeutic effects.
Therefore, to get drug candidates that show appropriate
pharmacokinetics, a long period and a high cost should
be consumed. It should be also pointed out that a large
number of mammals have been sacrificed for evaluation
of pharmacokinetics of drug candidate, and arguments of
ethical issues from the view of animal protection have
been arisen. Use of silkworm to evaluate pharmacokinet-
ics of chemicals will be a clue to overcome those prob-
lems.
Methods
Animals
Fertilized eggs of silkworm (Hu•Yo × Tsukuba•Ne) were
purchased from Ehime Sanshu (Ehime, Japan). Hatched
l a r v a e  w e r e  r e a r e d  a t  2 7  ° C  w i t h  S i l k m a t e  2 S  ( N i h o n
Nosan Kogyo, Tokyo, Japan), an artificial diet for young
silkworms to 4th instar. Larvae of 5th instar were fed with
Chisan 2-rei (Katakura Kogyo, Tokyo Japan), an artificial
diet for silkworms at the last stage. Humidity and light
cycle were not controlled.
Chromatography
HPLC analysis was performed by a column of PEGASIL
ODS (4.5φ × 250 mm) with isocratic elution of 10%
CH3CN for 15 min, followed by gradient elution of 10%-
100% CH3CN for 40 min, and then 100% CH3CN 15 min
at the flow rate of 1 ml/min. Preparative HPLC was car-
ried out by a column of PEGASIL ODS (20φ × 250 mm)
with isocratic elution of 40% CH3CN at the flow rate of 9
ml/min. Preparative thin layer chromatography was done
with 25 HPTLC plates RP-18 F254S (Merck) with a devel-
oping solution of hexane and ethyl acetate (3:1), or with
Silica gel 60F254 (Merck) with a developing solution of
chloroform and methanol (2:1).
Structural analysis
Structures of chemicals were analyzed by 1H-NMR or
F AB-MS (low resolution fast atom bombardment mass
spectrometry), and their spectrometric data were ana-
lyzed and compared with the results reported previously.
1H-NMR spectrometry was performed with a JEOL EC-
500 spectrometry meter. Samples were dissolved in
CDCl3 (Merck, NJ, USA). FAB-MS spectrometric data
was obtained with a JEOL JMS-700 mass spectrometer
(JEOL). Glycerol (Sigma) was used as a matrix.
Determination of chemicals in hemolymph of silkworms
A sample solution (50 μl) was injected into hemolymph of
5th instar larvae (1.8-2.0 g) with a syringe. Hemolymph
was harvested from legs and mixed with an equal volume
of acetone, followed by centrifugation at 15, 000 rpm for 5
min at 4 °C. Supernatant was dried up, dissolved into 50%
methanol to prepare for an HPLC sample. Standard
curves of each compound were drawn by measurement of
Figure 3 Chemical structures. Chemical structures of Compound A (Nobiletin), Compound B (Heptamethoxyflavone), and Compound C (Tangere-
tin).
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peak area on HPLC charts, and the amounts of each com-
pound in the sample were determined.
Injection of samples into silkworms
Samples were injected as previously described (4). Briefly,
for intra-midgut injection, samples were injected toward
the center of the body cavity from the 5th somite of the
abdomen of a living silkworm using a 27-gauge needle.
For intra-hemolymph injection, a 27-gauge needle was
inserted parallel to the outer skin at the 5th somite of the
abdomen. The accuracy of these injection techniques was
confirmed using trypan blue, which did not leak out from
t h e  m i d g u t  ( a d d i t i o n a l  f i l e  5 )  [ 6 ] .  L e s s  t h a n  1 %  o f  t h e
injection sample was detected in the hemolymph imme-
diately after the injection of compound C into the midgut
(additional file 6).
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Figure 4 Time course of decrease in concentrations of Nobiletin, 
Heptamethoxyflavone, and Tangeretin in silkworm hemolymph. 
A: Nobiletin; B: Heptamethoxyflavone; C: Tangeretin
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